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Abstract  Chronic  liver  disease  and/or  portal  hypertension  may  be  associated  with  one  of
the two  pulmonary  vascular  complications:  portopulmonary  hypertension  and  hepatopulmonary
syndrome.  These  pulmonary  vascular  disorders  are  notoriously  underdiagnosed;  however,  they
have a  substantial  negative  impact  on  survival  and  require  special  attention  in  order  to  under-
stand their  diagnostic  approach  and  to  select  the  best  therapeutic  options.  Portopulmonary
hypertension  results  from  excessive  vasoconstriction,  vascular  remodeling,  and  proliferative
and thrombotic  events  within  the  pulmonary  circulation  that  lead  to  progressive  right  ventri-
cular failure  and  ultimately  to  death.  On  the  other  hand,  abnormal  intrapulmonary  vascular
dilations,  profound  hypoxemia,  and  a  wide  alveolar-arterial  gradient  are  the  hallmarks  of  the
hepatopulmonary  syndrome,  resulting  in  difﬁcult-to-treat  hypoxemia.  The  aim  of  this  review  is
to summarize  the  latest  pathophysiologic  concepts,  diagnostic  approach,  therapy,  and  progno-
sis of  portopulmonary  hypertension  and  hepatopulmonary  syndrome,  as  well  as  to  discuss  the
role of  liver  transplantation  as  a  deﬁnitive  therapy  in  selected  patients  with  these  conditions.
© 2012  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.PALABRAS  CLAVE
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Complicaciones  vasculares  pulmonares  en  hipertensión  pulmonar  y  enfermedades
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Resumen  La  hipertensión  portal  con  o  sin  hepatopatía  crónica  puede  estar  asociada  a  compli-
caciones en  la  vasculatura  pulmonar,  en  concreto  al  desarrollo  de  hipertensión  portopulmonar  y
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al  síndrome  hepatopulmonar.  Dichas  entidades  nosológicas  son  claramente  subdiagnosticadas;
sin embargo,  conﬁeren  un  impacto  negativo  en  la  sobrevida  y  el  pronóstico  de  estos  enfermos,
requiriendo  especial  atención,  con  el  ﬁn  de  establecer  una  estrategia  adecuada  en  cuanto  al
abordaje diagnóstico  y  las  implicaciones  y  conductas  terapéuticas  a  seguir  ante  su  detección.  La
hipertensión  portopulmonar  resulta  de  una  remodelación  vascular  pulmonar  que  incluye  fenó-
menos vasoconstrictivos,  proliferativos  y  protrombóticos  en  la  circulación  pulmonar,  llevando
a la  insuﬁciencia  ventricular  derecha  progresiva  y  a  la  muerte.  Por  otro  lado,  las  dilataciones
vasculares  intrapulmonares  anormales,  la  hipoxemia  signiﬁcativa  y  el  incremento  en  el  gradi-
ente alvéolo-arterial  caracterizan  al  síndrome  hepatopulmonar,  siendo  un  reto  terapéutico  el
manejo de  la  hipoxemia  refractaria.  Esta  revisión  se  enfocará  a  sintetizar  los  aspectos  ﬁsiopa-
tológicos, el  abordaje  diagnóstico  y  terapéutico,  así  como  las  consideraciones  pronósticas  de  la
hipertensión  portopulmonar  y  del  síndrome  hepatopulmonar,  además  de  describir  el  papel  del
trasplante hepático  como  terapia  deﬁnitiva  en  pacientes  seleccionados.
© 2012  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
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hronic  liver  disease  and/or  portal  hypertension  are  lead-
ng  causes  of  morbidity  and  mortality  among  the  Western
dult  population  and  have  been  associated  with  two  par-
icular  pulmonary  vascular  complications,  portopulmonary
ypertension  (POPH)  and  hepatopulmonary  syndrome  (HPS),
esulting  in  signiﬁcant  morbidity  and  mortality,  particularly
n  the  setting  of  end-stage  liver  disease  requiring  liver  trans-
lantation  (LT).  In  the  last  decade  there  has  been  increasing
wareness  and  recognition  of  these  entities,  especially  when
T  is  being  considered,  inﬂuencing  the  pre-,  trans-  and
ost-transplant  outcomes.  HPS  is  characterized  by  intrapul-
onary  vascular  dilatation  and  hypoxemia,  while  POPH  is
haracterized  by  increased  pulmonary  vascular  resistance
PVR)  and  mean  pulmonary  arterial  pressures  (mPAP).1 This
eview  will  focus  on  the  relevant  clinical  aspects  of  both
OPH  and  HPS,  providing  the  clinician  with  the  tools  to  guide
im  in  the  care  of  this  complex  subset  of  patients.
ortopulmonary hypertension (POPH)
eﬁnition
OPH  is  best  deﬁned  as  a  condition  characterized  by
ncreased  mean  pulmonary  arterial  pressure  (mPAP)  and
ulmonary  vascular  resistance  (PVR),  resulting  in  pul-
onary  arterial  hypertension  (PAH)  in  association  with
ortal  hypertension,  whether  or  not  portal  hypertension
s  related  to  underlying  chronic  liver  disease  or  not.1,2
t  the  2008  Dana  Point  World  symposium  on  pulmonary
ypertension  (PH),  POPH  was  classiﬁed  within  the  World
ealth  Organization  (WHO)  PH  group  1,  becoming  part
f  one  of  the  associated  forms  of  PAH.3,4 Currently,  spe-
iﬁc  hemodynamic  criteria  exist  for  the  accurate  deﬁnition
nd  diagnosis  of  POPH.  These  hemodynamic  parameters
equire  performing  a  right  heart  catheterization  in  which
he  following  measurements  are  obtained:  mPAP  >  25  mmHg
t  rest,  PVR  >  240  dynes/s/cm−5 (or  >3  Woods  units;  1
ood  unit  =  80  dynes/s/cm−5),  and  a  mean  pulmonary
rterial  occlusion  pressure  (mPAOP)  <  15  mmHg  or  a  transpul-
onary  gradient  (TPG,  the  difference  between  mPAP  and
PAOP)  >  12  mmHg.5 TPG  sometimes  can  be  helpful  for
l
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clinicians  when  the  assessment  of  PVR  and/or  the  mPAOP
o  not  meet  the  current  criteria.  We  believe  that  under-
tanding  the  cardiopulmonary  hemodynamics  and  physiology
n  patients  with  portal  hypertension  and  liver  disease
s  of  paramount  importance,  since,  in  general,  patients
ith  advanced  liver  disease  suffer  from  hyperdynamic
ardiovascular  system,  characterized  by  high  cardiac  out-
ut  (CO)  and  low  peripheral  vascular  resistance  and
rterial  hypotension,  as  well  as  increased  blood  volume
ue  to  ﬂuid  and  electrolyte  imbalances  typically  seen
n  advanced  cirrhosis.  Hemodynamically  this  results  in
levated  mPAP,  CO,  and  mPAOP  with  a  normal  or  low
VR.  Interestingly,  approximately  30--50%  of  patients  with
hronic  liver  disease  have  decreased  systemic  vascular
esistance,  low  PVR  and  elevated  CO,  making  the  ele-
ations  in  mPAP  due  to  the  increased  CO,  leading  some
nvestigators  and  researchers  to  propose  a  new  cutoff  for
VR  >  120  dynes/s/cm−5 to  be  used  as  a  novel  deﬁnition  of
OPH.6,7
pidemiology
he  incidence  and  prevalence  of  POPH  is  difﬁcult  to  assess
nd  is  not  well  deﬁned.  POPH  is  a  relatively  rare  condition;
owever,  most  commonly  observed  among  patients  being
valuated  for  LT,  where  it  has  been  reported  in  6--8%  of
he  patients  with  end-stage  liver  disease.8,9 In the  French
ational  registry  for  pulmonary  hypertension  (PH),  patients
ith  POPH  accounted  for  10%  of  the  PAH  population,  just
ehind  idiopathic  PAH  (iPAH),  PAH  associated  with  congeni-
al  heart  disease  and  PAH  associated  with  connective  tissue
isorders.10 Reports  on  the  prevalence  of  POPH  have  varied
reatly  over  the  last  ten  years,  which  may  be  the  reﬂection
f  changing  clinical  practices  by  adopting  a  better  screening
nd  diagnostic  work-up,  particularly  in  patients  undergoing
T  evaluation.11
POPH  is  commonly  diagnosed  4--7  years  after  the  pres-
nce  of  portal  hypertension  has  been  established,  and
s  most  commonly  described  during  the  ﬁfth  decade  of
ife.12 Kawut  et  al.13 performed  an  observational  prospec-
ive  cohort  study  to  evaluate  the  risk  factors  for  the
evelopment  of  POPH,  and  found  that  female  sex  was  asso-
iated  with  a  higher  risk  for  POPH  than  male  sex,  and
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nLung  vascular  disorders  in  liver  disease  
also  autoimmune  hepatitis  as  etiology  of  liver  disease  was
more  commonly  associated  to  POPH  than  other  etiologies,
whereas  chronic  hepatitis  C  infection  was  less  likely  to
be  associated  with  POPH,  concluding  that  hormonal  and
immunologic  factors  could  play  an  important  role  for  the
development  of  POPH.  Krowka  et  al.14 evaluated  the  sur-
vival  and  hospitalization  rates  in  the  Registry  to  Evaluate
early  and  long-term  PAH  disease  management  (REVEAL  reg-
istry)  of  patients  with  POPH  when  compared  with  iPAH;
ﬁnding  that  POPH  patients  had  signiﬁcantly  poorer  survival
rates  compared  with  iPAH,  of  note,  POPH  patients  were  less
likely  to  be  in  PAH-speciﬁc  vasodilator  therapy.  Interest-
ingly,  the  severity  of  chronic  liver  disease  as  estimated  by
the  Child-Pugh  score  or  the  Model  for  End-stage  Liver  Dis-
ease  (MELD)  score  were  not  associated  with  the  presence
or  severity  of  POPH.9,13 Le  Pavec  et  al.15 retrospectively
analyzed  the  charts  of  patients  referred  to  the  French  refer-
ral  center  for  PAH,  evaluating  154  patients,  ﬁnding  that  the
presence  and  severity  of  cirrhotic  liver  disease  and  cardiac
index  were  the  major  independent  prognostic  factors  for
survival.
Pathophysiology
POPH  is  pathobiologically  indistinct  when  compared  with
other  forms  of  PAH.  The  pulmonary  endothelium  is  a
complex  system  and  the  pathogenesis  of  POPH  is  not  com-
pletely  understood;  however,  the  vascular  remodeling  that
takes  place  in  POPH  is  likely  an  end-product  of  the  com-
plex  interaction  and  dysregulation  of  numerous  vasoactive,
proliferative,  angiogenic  and  prothrombotic  signals  and
modulators.1,2 Most  of  the  theories  to  try  to  explain  the
pathophysiology  of  POPH  have  been  derived  from  recent
advances  in  the  cellular  and  molecular  studies  on  iPAH.
A  signiﬁcant  up-regulation  of  the  potent  pulmonary  vaso-
constrictor  and  proliferator  endothelin-1  (ET-1)  has  been
found  in  patients  with  POPH,  and  is  thought  likely  to  result
from  the  impaired  clearance  or  increased  production  of  ET-1
by  the  deranged  liver.16 Down-regulation  or  decreased  levels
of  prostaglandin  I-2  (prostacyclin)  synthase  have  also  been
found  in  patients  with  PAH,  including  those  with  POPH.17
A  proposed  mechanism  for  the  development  of  POPH
includes  the  initial  and  constant  shear  stress  and  increased
blood  ﬂow  (high  cardiac  output  status)  in  liver  disease,
activating  a  cascade  of  events  that  may  eventually  lead
to  pulmonary  endothelial  dysfunction  and  pulmonary  vas-
cular  remodeling.18 Another  hypothesis  that  has  been
proposed  is  that  toxic  products  from  the  digestive
tract  that  are  normally  metabolized  and  cleared  in  the
liver  bypass  the  liver  via  portosystemic  shunts,  directly
damaging  the  pulmonary  vascular  endothelium.19 The  devel-
opment  of  portosystemic  shunts,  a  decrease  in  liver
phagocytic  capacity,  and  increased  frequency  of  bacte-
rial  translocation  facilitate  the  expression  and  activation
of  pro-inﬂammatory  cytokines,  pro-angiogenic  factors  and
bacterial  endotoxins  which  probably  induce  pulmonary
endothelium  damage  and  dysfunction.20 These  changes
ultimately  lead  to  increased  PVR  and  increased  right
heart  workload,  which  then  result  in  the  changes  seen
at  the  time  of  right  heart  catheterization  as  described
earlier.
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iagnosis
ost  patients  with  POPH  are  asymptomatic  at  the  time  of
iagnosis,  and  hence  a  high  index  of  suspicion  is  needed
o  identify  this  condition  in  patients  with  cirrhotic  or  non-
irrhotic  portal  hypertension.  When  symptoms  are  present,
hey  generally  include  dyspnea  on  exertion,  fatigue  and  in
ore  severe  cases,  chest  pain,  orthopnea,  hemoptysis  and
yncope.21,22 On  physical  examination  patients  can  present
ith  a  loud  pulmonic  valve  closure  (P2),  split  second  heart
ound,  and  tricuspid  insufﬁciency  murmur  and  right  ventri-
ular  heave.  Also  common  are  signs  of  right  heart  failure
uch  as  increased  jugular  venous  pressure,  right-sided  S3  or
4  gallop,  lower  extremity  edema  and  pulsatile  liver.22 The
resence  of  symptoms  and/or  signs  of  pulmonary  hyperten-
ion  in  a  patient  with  portal  hypertension  should  lead  the
linician  to  consider  POPH  in  the  differential  diagnosis  and
o  embark  in  further  diagnostic  evaluation.  The  main  dif-
erential  diagnoses  include  idiopathic  PAH,  PAH  associated
ith  collagen  vascular  disease,  thromboembolic  disease,
nfection  with  human  immunodeﬁciency  virus  (especially  in
atients  with  chronic  viral  hepatitis  B  or  C),  or  PAH  associ-
ted  with  primary  cardiac  or  lung  diseases.23 The  clinician
hould  also  consider  other  causes  of  cardiopulmonary  symp-
oms  in  the  cirrhotic  patient,  including  ascites,  hepatic
ydrothorax,  sarcopenia  and  muscle  waisting,  decondition-
ng,  anemia  and  hepatopulmonary  syndrome  (HPS).24
After  a  thorough  history  and  physical  exam,  the  most
seful  tool  to  aid  in  the  diagnosis  of  POPH  is  transthoracic
chocardiography  (TTE),  with  a  sensitivity  >95%  and  speci-
city  close  to  80--90%.25,26 The  parameter  used  to  best  assess
ulmonary  pressure  is  the  right  ventricular  systolic  pres-
ure  (RVSP)  or  pulmonary  artery  systolic  pressure  (PASP).26
TE  can  also  provide  detailed  information  on  the  function
f  the  right  ventricle  that  is  complementary  to  the  RVSP
easurement  and  improves  our  ability  to  determine  the  clin-
cal  consequences  of  POPH  in  a  speciﬁc  patient.27 Of  note,
p  to  20--30%  of  patients  undergoing  TTE  do  not  have  tri-
uspid  regurgitation  and  hence  RVSP  cannot  be  estimated.
ortunately,  most  of  these  patients  will  not  have  pulmonary
ypertension,  and  hence  no  further  work-up  is  necessary.9
A  RVSP  cutoff  of  30--50  mmHg  has  been  used  by  dif-
erent  institutions  to  select  patients  who  require  further
iagnostic  evaluation.9,28 Although  several  non-invasive
odalities  have  been  evaluated,  the  current  diagnostic
‘gold-standard’’  remains  right  heart  catheterization.  The
emodynamic  measurements  at  the  time  of  right  heart
atheterization  are  indispensable  to  differentiate  increases
n  mPAP  from  a  hyperdynamic  state  or  from  volume  over-
oad,  both  common  in  the  cirrhotic  patient,  from  true  POPH,
hich  will  by  deﬁnition  have  not  only  a  mPAP  >  25  mmHg  but
lso  a  PVR  >  240  dynes/s/cm−5 and  a  mPAOP  <  15  mmHg  or  a
PG  >  12  mmHg,  as  described  earlier.2
In  the  recent  past,  several  research  groups  have
ttempted  to  improve  our  ability  to  diagnose  POPH  using
on-invasive  methods.  Tsiakalos  et  al.  evaluated  the  serum
evels  of  endothelin  (ET)  1,  2  and  3  and  described  a  sig-
iﬁcant  increase  in  ET-1  and  ET-1  to  ET-3  ratio  in  patients
ith  POPH  as  deﬁned  by  an  RVSP  >  40  mmHg  compared  to
atients  with  normal  RVSP.29 Pellicelli  et  al.  showed  sig-
iﬁcantly  increased  levels  of  serum  ET-1  and  interleukin
 among  patients  with  POPH  in  comparison  to  cirrhotic
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atients  with  or  without  hyperdynamic  circulation  diagnosed
y  right  heart  catheterization.30 Potentially  more  useful  in
linical  practice  are  the  ﬁndings  of  Bernal  et  al.  on  the
se  of  N-terminal  natriuretic  peptide  type  B  (NT-proBNP)  in
atients  with  cirrhosis  and  POPH.  They  were  able  to  demon-
trate  increased  serum  levels  of  NT-proBNP  in  patients  with
PAP  >  25  mmHg  on  right  heart  catheterization  compared
o  patients  with  lower  mPAP  (1950  ±  1245  vs.  1407  ±  945,
 =  0.04)  and  demonstrated  a  weak  correlation  between
T-proBNP  levels  and  severity  of  pulmonary  hypertension
mPAP)  on  right  heart  catheterization.31,32 In  the  future  it
ight  be  possible  to  accurately  distinguish  cirrhotic  patients
ith  POPH  vs.  those  with  other  causes  of  elevated  RVSP  on
TE  without  the  need  for  right  heart  catheterization,  but
or  now  this  invasive  and  costly  diagnostic  test  continues  to
e  the  gold-standard  of  diagnosis  and  monitoring  of  therapy
or  PAH.
herapy
OPH  is  a  progressive  and  lethal  disease.  If  left  untreated,
oderate  to  severe  POPH  has  a  mortality  rate  of  54%  within
 year  and  a  dismal  14%  survival  rate  at  ﬁve  years.33 Con-
ersely,  if  treated  successfully,  a  45%  survival  rate  at  5
ears  can  be  expected.33 Despite  having  better  hemody-
amics  measurements  at  baseline  and  better  hemodynamic
esponse  to  therapy,  POPH  fairs  worse  than  iPAH.  This
uggests  that  factors  other  than  pulmonary  hemodynam-
cs  participate  in  the  poor  long-term  survival  of  these
atients.33,34 Recently,  Talwalkar  et  al.  have  demonstrated
hat  large  portosystemic  shunts  deﬁned  as  a  greater  than
0  mm  in  diameter  were  associated  with  poor  response  to
reatment  in  68%  of  study  patients  with  POPH.35
The  role  of  speciﬁc  therapies  for  POPH  remains  unclear
ince  a  therapeutic  approach  has  never  been  scientiﬁcally
valuated.  Nonetheless,  as  POPH  is  classiﬁed  within  the
HO  group  1  PAH,36 therapies  that  have  been  FDA  approved
o  treat  PAH  have  been  considered  adequate  to  treat  POPH.
The  main  goal  of  therapy  in  POPH  is  to  improve  exer-
ise  tolerance,  quality  of  life,  reduce  symptoms  and  reach
 hemodynamic  response  that  will  facilitate  LT  when
ndicated.37 The  usual  approach  to  treating  POPH  is  to
nitiate  therapy  when  mPAP  is  >35  mmHg  on  right  heart
atheterization,  with  a  ﬁnal  goal  to  reduce  mPAP  to
 35  mmHg  and  PVR  to  <400  dynes/s/cm−5,  so  patients  can
e  considered  for  liver  transplantation,  as  further  discussed
n  the  corresponding  section.
POPH  is  treated  with  the  same  general  measures  that
re  used  to  treat  iPAH.38 The  aim  of  these  therapies  is  to
nload  the  right  ventricle  and  prevent  right  ventricular  fail-
re.  Diuretics,  supplemental  oxygen,  low  salt  diet,  weight
ontrol,  routine  inﬂuenza  and  pneumonia  immunizations,
ild  to  moderate  exercise  and  participation  in  local  sup-
ort  groups  for  PAH  are  useful  to  improve  quality  of  life  and
mprove  symptoms.  The  use  of  calcium  channel  blockers,
eta  blockers  and  anticoagulation  are  not  recommended
n  POPH.1 The  calcium  channel  blockers  have  the  poten-
ial  of  producing  mesenteric  vasodilatation  that  may  worsen
ortal  hypertension.39 Beta  blockers  with  their  negative
notropic  and  chronotropic  effects  worsen  exercise  capac-
ty  and  pulmonary  hemodynamics.40 Although  chronic  oral
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nticoagulation  is  indicated  in  iPAH,  it  is  not  generally  indi-
ated  in  POPH  due  to  the  high  risk  of  bleeding  associated
ith  the  presence  of  esophageal  varices.
In  the  past  15  years,  new  targeted  therapies  have
een  approved  by  the  FDA  to  treat  PAH.  Three  different
roups  of  medications  are  currently  available:  prostacy-
lin  analogs,  endothelin  receptor  antagonist  (ERAs)  and
hosphodiesterase-5  inhibitors  (PD-5).
Although  randomized  trials  have  never  been  performed
n  POPH,  several  case  series  and  retrospective  studies  have
hown  substantial  response  to  therapy;  as  deﬁned  by  a  >20%
ecline  in  PVR  after  12  weeks  of  treatment.41 Furthermore,
hese  studies  revealed  improvements  in  exercise  tolerance
nd  overall  survival,  as  well  as  a  decrease  in  mPAP  to  values
here  LT  is  possible  (Table  1).  Of  note,  inhaled  prostacyclin
oes  not  improve  long-term  hemodynamics  when  used  as
onotherapy.42,43 Up  to  now,  IV  or  SQ  prostacyclin  has  been
onsidered  the  drug  of  choice  to  treat  POPH  with  the  inten-
ion  of  future  liver  transplantation.  Unfortunately,  only  few
atients  may  be  able  to  reach  an  mPAP  that  will  allow  liver
ransplantation.  In  addition,  IV/SQ  prostacyclin  is  delivered
t  a  high  ﬁnancial  cost  and  at  high  risk  of  complications
nd  side  effects.  Since  therapies  other  than  prostacyclin
ffer  similar  beneﬁts,  a  plausible  therapeutic  intervention
alls  for  initiation  of  a  goal  oriented  therapy  as  described
y  Hoeper  et  al.  with  a  minor  protocol  modiﬁcation.44
atients  will  need  a  follow-up  right  heart  catheterization
o  re-evaluate  mPAP  and  PVR.  The  protocol  calls  for  regular
linical  follow-up  at  1--6  months  with  interval  measurement
f  the  6-min  walk  test,  functional  assessment  of  dyspnea  and
emodynamic  data  at  3--6  months  of  therapy.  Treatment  can
deally  start  with  an  oral  agent,  preferably  ERAs,  since  the
emodynamic  improvement  of  PD-5  seems  to  plateau  after
 months.  After  the  addition  of  a  second  oral  agent,  the
ddition  of  a  third  medication  will  depend  on  the  clinical
nd/or  hemodynamic  response  and  the  patient’s  candidacy
or  LT.  This  protocol  may  reduce  the  need  for  prostacyclin
reatment  and  better  select  those  patients  who  will  beneﬁt
rom  liver  transplantation.
All  FDA  approved  therapies  for  PAH  increase  cardiac
utput  and  have  the  potential  of  worsening  portal  hyperten-
ion  and  inducing  hypersplenism  by  increasing  the  hepatic
enous  pressure  gradient.  Although  described  with  prostac-
clin  analogs,45 this  particular  situation  is  rare  but  more
requent  than  in  iPAH.  In  regards  to  the  increase  in  hepatic
enous  pressure,  only  Melgosa  et  al.  have  studied  the  acute
nd  chronic  hemodynamic  responses  to  inhaled  prostac-
clin.  They  demonstrated  that  the  acute  and  long-term
ffect  of  inhaled  prostacyclin  produces  rapid  and  selec-
ive  pulmonary  vasodilatation  without  altering  the  hepatic
emodynamics.43 Patients  with  POPH  generally  die  from  PH
elated  problems  with  right-heart  failure,  progression  of
heir  liver  disease,  infectious  complications  and  sepsis,  and
rom  hepatocellular  cell  carcinoma.
OPH  and  liver  transplantationecause  of  its  mostly  asymptomatic  presentation  and  its
igniﬁcant  consequence  to  clinical  outcomes  after  LT,  all
atients  with  cirrhosis  being  considered  for  transplantation
hould  be  screened  for  POPH.  Due  to  its  usefulness  as  a
Lung  vascular  disorders  in  liver  disease  39
Table  1  Current  speciﬁc  medical  therapies  for  portopulmonary  hypertension.
Drug  Number  of
patients
MELD  or
Child-Pugh  score
>21%  decrease
in  PVR
Remarks
Prostacyclin
Swanson  et  al.  (IV  epoprostenol)33 35  13  Yes  5-year  survival  of  45%
Fix et  al.  (IV  epoprostenol)34 19  14  Yes  2  underwent  LT
Ashfaq et  al.  (IV  epoprostenol)37 16  12--15  Yes  11  underwent  LT,  5-year
survival  of  43%
Hoeper et  al.  (Inhaled  iloprost)42 18  A--B  No  5-Year  survival  of  46%
Melgosa et  al.  (Inhaled  iloprost)43 12  11  No  91%  alive  at  1  year
Endothelin receptor  antagonists
Hoeper  et  al.  (Bosentan)42 18 A Yes 5-Year  survival  of  89%
Cartin-Ceba  et  al.  (Ambrisentan)83 13 10 Yes 11  of  13  alive  at  1  year
Halank et  al.  (Ambrisentan)84 14  10  Yes  12/14  alive  at  1  year
Phosphodieasterase-5  inhibitors
Gough  et  al.  (sildenaﬁl)85 11  B--C/14  Yes  1  underwent  LT,  9
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increases  morbidity  and  mortality  among  patients  with  end-screening  tool  the  American  Association  for  the  Study  of
Liver  Diseases  (AASLD)  recommends  that  all  patients  eval-
uated  for  liver  transplantation  undergo  TTE  and  that  if  RVSP
is  elevated,  further  evaluation  with  right  heart  catheteriza-
tion  is  warranted.46 Some  authors  recommend  periodically
screening  patients  on  the  transplant  wait  list  with  TTE  to
look  for  new  cases  of  POPH,  as  it  can  at  times  develop
quite  rapidly  and  may  not  be  present  on  initial  transplant
evaluation.11
A  right  heart  catheterization  provides  not  only  an  accu-
rate  diagnosis  of  POPH,  it  also  allows  the  assessment  of  the
severity  of  POPH,  which  has  prognostic  implications  in  LT.
Patients  with  mild  POPH  (mPAP  of  25--34  mmHg)  have  simi-
lar  perioperative  and  postoperative  morbidity  and  mortality
after  LT  than  patients  without  POPH  and  can  proceed  to  LT
without  further  intervention,  while  patients  with  moderate
POPH  (mPAP  of  35--44  mmHg)  have  a  high  risk  of  periopera-
tive  and  post-transplant  mortality  and  should  be  targeted  for
therapy  to  reduce  mPAP  to  <35  mmHg  prior  to  LT  (see  section
on  therapy).  Patients  with  severe  POPH  (mPAP  ≥  45  mmHg)
should  be  excluded  from  LT  as  it  results  in  an  exceedingly
high  mortality  rate.47
As  POPH  does  not  always  resolve  after  transplantation,
it  is  not  considered  as  an  indication  for  LT.  This  is  different
from  HPS,  which  clearly  improves  after  LT  and  is  one  of  the
indications  for  transplant.  Although  POPH  has  been  shown  to
resolve  after  LT  in  some  patients,  it  has  also  been  described
that  others  require  long-term  pulmonary  vasodilator  ther-
apy  after  LT  and  that  yet  others  suffer  from  worsening  PAH
after  LT  and  there  are  even  case  reports  of  PAH  develop-
ing  ‘‘de-novo’’  after  transplant.  Nonetheless,  in  the  United
States  the  United  Network  for  Organ  Sharing  (UNOS)  allows
patients  with  mild  to  moderate  POPH  be  listed  for  LT  and
provides  MELD  exception  points  (MELD  score  =  26)  if  the
LT  candidate  satisﬁes  the  following  criteria:  (a)  conﬁrmed
POPH  by  right  heart  catheterization  with  mPAP  >  35  mmHg;
(b)  at  least  12  weeks  of  approved  PAH  therapy  that
results  in  mPAP  <  35  mmHg  and  PVR  <  400  dynes/s/cm−5 with
a  satisfactory  right  ventricular  function  as  assessed  by
the  individual  transplant  center.  If  the  patient  is  not
s
aof 11  alive  at  3  years
ransplanted  within  a  6-month  period,  additional  MELD
xception  points  may  be  granted  after  approval  by  the
egional  review  board.48 Patients  with  moderate  POPH
efractory  to  medical  therapy  or  with  severe  POPH  are  rou-
inely  excluded  from  LT  due  to  the  very  high  mortality  after
T.  Recently  though,  cases  of  combined  heart,  lung  and  liver
r  combined  lung  and  liver  transplant  have  been  described
o  address  this  speciﬁc  issue.  Clearly  this  should  only  be
ndertaken  by  very  experienced  centers  in  highly  selected
atients.49,50
epatopulmonary syndrome
eﬁnition
ardiovascular  abnormalities  are  present  in  most  patients
ith  advanced  liver  disease.  The  term  ‘‘hepatopulmonary
yndrome’’  (HPS)  was  coined  by  Kennedy  and  Knudson  in
977.51 This  syndrome  is  characterized  by  defects  in  arterial
xygenation  as  a  consequence  of  shunting  through  pul-
onary  vascular  dilatations  in  the  setting  of  liver  disease,5,52
nd  has  three  classical  components:  liver  disease,  intrapul-
onary  vascular  dilatations  (IPVD),  and  poor  oxygenation.
he  oxygenation  defect  involves  a  widened  aged-corrected
lveolar-arterial  oxygen  gradient  (P[A-a]O2)  at  room  air,
ith  or  without  concomitant  hypoxemia.5
HPS  may  present  in  patients  with  or  without  portal
ypertension  in  the  setting  of  acute  or  chronic  liver  dis-
ase.  Indeed  it  may  be  present  in  patients  with  acute  liver
ailure.  There  is  only  a  weak  association  between  the  sever-
ty  of  the  liver  disease  and  the  degree  of  hypoxemia  and
he  cause  of  liver  disease  does  not  seem  to  be  related
ith  the  development  of  HPS.53 HPS  may  occur  in
atients  with  other  comorbidities,  including  cardiopul-
onary  conditions.54 Of  relevance  is  the  fact  that  HPStage  liver  disease  awaiting  LT.55
In  HPS  hypoxemia  is  deﬁned  on  the  basis  of  an  increased
lveolar-arterial  oxygen  gradient,  P[A-a]O2 ≥  15  mmHg  in
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procedure.  This  grading  system  is  based  on  oxygenation
abnormalities  in  four  stages,  as  depicted  in  Table  2.  As  these
oxygenation  abnormalities  become  more  severe,  much  more
so  is  their  impact  on  the  patients’  quality  of  life  and  the
Table  2  Grading  of  severity  of  hepatopulmonary
syndrome.
Stagea P[A-a]O2
(mmHg)b,d
PaO2 (mmHg)c
Mild  ≥15  ≥80
Moderate  ≥15  <80  to  ≥60
Severe  ≥15  <60  to  ≥50
Very  Severe  ≥15  <50  (<300  on  100%  O2)
P[A-a]O2: alveolar-arterial oxygen tension difference, the
abbreviated formula for alveolar-arterial gradient is as
follows: PAO2--PaO2 = (FiO2[Patm--PH2O] − [PaCO2/0.8]) − PaO2,
where PAO2 denotes partial pressure of alveolar oxygen, PaO2
partial pressure of arterial oxygen, FiO2 fraction inspired oxy-
gen, Patm atmospheric pressure, PH2O partial pressure of water
vapor at body temperature, and PaCO2 partial pressure of arte-
rial carbon dioxide. PaO2: arterial oxygen tension.
a All with positive contrast-enhanced echocardiography.
b Normal range 4--8 mmHg.0  
dults  or  P[A-a]O2 ≥  20  mmHg  in  patients  older  than  64  years
f  age,  at  sea  level,  and  at  room  air  (FiO2 21%).  This  method
s  the  most  sensitive  to  detect  early  deoxygenation,  even
efore  arterial  oxygen  tension  (PaO2)  becomes  abnormally
ow.5 However,  the  presence  of  hypoxemia  is  not  sufﬁcient
o  deﬁne  HPS,  it  must  be  accompanied  by  IPVD  (deﬁned  as
ncreased  pulmonary  capillary  diameter  ranging  from  15  to
0  m)  as  assessed  by  the  presence  of  an  abnormal  contrast-
nhanced  echocardiography  (CEE)  and/or  perfusion  lung
canning  with  technetium-99m-labeled  macroaggregated
lbumin  (99  TcMAA).
athogenesis  and  pathophysiology
he  main  pathologic  features  of  HPS  include  gross  dilata-
ion  of  the  pre-capillary  and  capillary  pulmonary  vessels
to  15--100  m  in  diameter),  pleural  and  pulmonary  arterio-
enous  shunts  and  portopulmonary  venous  anastomoses.  The
bove  vascular  abnormalities  result  in  impaired  oxygen-
tion  of  venous  blood  as  it  passes  through  the  pulmonary
irculation.  The  pulmonary  vascular  dilatation  results  in
he  passage  of  mixed  venous  blood  either  rapidly  or  even
irectly,  through  intrapulmonary  shunts,  into  the  pulmonary
eins.  The  defect  in  oxygenation  is  due  to  a  ventilation-
erfusion  mismatch  characterized  by  increased  blood  ﬂow
hile  alveolar  ventilation  is  preserved;  this  phenomenon
s  enhanced  by  the  absence  or  impairment  of  hypoxic  pul-
onary  vasoconstriction.18
Experimental  and  clinical  data  suggest  that  increased
roduction  of  nitric  oxide  (NO)  in  the  lungs  plays  a  cen-
ral  role  in  the  pathogenesis  of  HPS.  This  potent  vasodilator
as  been  linked  to  vascular  abnormalities.  Increased  intra-
ulmonary  levels  of  NO  have  been  described  in  cirrhotic
atients  with  HPS,56 and  their  subsequent  normalization
fter  transplantation  were  associated  to  resolution  of
PS.57,58 Increased  expression  of  pulmonary  endothelial-cell
ndothelin  B  receptors  (ETB)  and  increased  hepatic  produc-
ion  and  release  of  ET-1  contribute  to  an  increase  in  eNOS
endothelial  Nitric  Oxide  Synthase)  expression  and  enhanced
O  production  in  an  animal  model  of  HPS.5,18
Recently,  angiogenesis  has  been  recognized  as  a  relevant
ontributor  to  the  pathophysiology  of  HPS  in  animal  models,
nd  is  mediated  by  the  activation  of  vascular  endothelial
row  factor  A  produced  in  part  by  activated  intravascular
onocytes.59 In  humans,  several  polymorphisms  in  the  genes
nvolved  in  the  regulation  of  angiogenesis  have  been  asso-
iated  with  the  risk  of  HPS  (CAV  3,  ENG, NOX4, ESR2, VWF,
UNX1,  COL18A1,  COL18A1  and  TI31).60,61
linical  manifestations
PS  is  typically  diagnosed  in  patients  with  cirrhosis  who
resent  with  shortness  of  breath,  cyanosis,  ﬁnger  clubbing
nd  clinically  signiﬁcant  hypoxemia  (PaO2 <  60  mmHg),  but
he  majority  of  patients  with  HPS  are  either  asymptomatic
r  develop  insidious  onset  of  dyspnea.  Dyspnea  on  exertion,
t  rest,  or  both  is  the  predominant  presenting  symptom;
owever,  this  symptom  is  a  nonspeciﬁc  ﬁnding,  and  there
re  no  hallmark  signs  on  physical  examination.
In  addition,  hypoxemia  may  worsen  (PaO2 arterial  blood
ecreased  ≤5%  or  4  mmHg)  when  the  patient  moves  fromM.  Porres-Aguilar  et  al.
upine  to  an  upright  position  (orthodeoxia),  which  produces
he  clinical  symptom  of  platypnea,  or  worsening  shortness
f  breath  on  standing.  This  clinical  feature  is  present  in  up
o  25%  of  patients  with  HPS.  This  clinical  phenomenon  is  a
eﬂection  of  increased  perfusion  of  the  lung  bases,  where
ascular  dilatation  predominates  in  HPS,  leading  to  wors-
ning  oxygen  exchange,  reduced  PaO2 and  the  increased
eeling  of  shortness  of  breath.5,18,62
Pulmonary  function  test  typically  demonstrate  a  reduced
arbon  monoxide  diffusion  capacity  in  the  presence  of  nor-
al  spirometric  volumes,  but  this  ﬁnding  is  not  speciﬁc  for
PS.62
Noticeably,  there  is  no  correlation  between  the  severity
f  HPS  and  the  severity  of  the  liver  disease,  on  basis  of  dif-
erent  models  of  liver  disease  severity  (i.e.  Child-Pugh  class
r  MELD  score).62
Clinicians  should  also  be  aware  that  common  chronic  pul-
onary  diseases  (i.e.  COPD,  asthma,  etc.)  can  coexist  in  a
hird  of  patients  with  HPS.5,55 Extrapulmonary  complications
ssociated  with  right  to  left  pulmonary  shunts  are  rare  and
nclude  brain  abscess  and  intracranial  hemorrhage.63,64 The
hysician  must  also  consider  the  syndrome  of  hereditary
emorrhagic  telangiectasia  (HHT  or  Rendu-Osler-Weber  syn-
rome)  in  the  differential  diagnoses  of  HPS,  as  it  shares  some
imilarities,  and  both  can  be  associated  with  severe  hypox-
mia  caused  by  pulmonary  vascular  dilatation,  which  may
e  diffuse  or  discrete  in  nature.
taging  of  severity
he  severity  of  HPS  not  only  directly  inﬂuences  patient  sur-
ival,  it  also  helps  the  clinician  make  decisions  regarding
iming  of  LT  and  the  risk  of  mortality  associated  with  thisc Normal range 100--80 mmHg (breathing room air at rest and
at sea level).
d For patients aged >64 years, a cut-off value for P[A-a]O2 ≥ 20.
¥ data from Rodriguez-Roisin et al.5
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TLung  vascular  disorders  in  liver  disease  
more  clinical  symptoms  are  apparent.  The  severity  of  HPS
should  also  prompt  the  physician  to  pursue  speciﬁc  ther-
apeutic  interventions  (e.g.  long  term  oxygen  therapy  and
embolotherapy)  to  improve  or  reverse  some  of  the  symptoms
and  limitations  associated  with  HPS.65,66
Epidemiology  and  natural  history
The  prevalence  of  HPS  in  patients  with  cirrhosis  and  end-
stage  liver  disease  ranges  from  4%  to  30%,67 and  the  differing
prevalence  is  primarily  due  to  heterogeneity  of  the  applied
diagnostic  criteria.
Poor  quality  of  life  and  increased  mortality  have  been
described  in  cirrhotic  patients  with  HPS,  and  survival  is
signiﬁcantly  decreased  compared  with  cirrhotic  patients
without  HPS.68 The  presence  of  HPS  worsens  the  prog-
nosis  of  patients  with  liver  disease,  regardless  of  liver
transplant  status.  Studies  in  patients  who  were  not  can-
didates  for  liver  transplant  have  shown  a  median  survival
of  87  months  and  a  5-year  survival  of  63%,  while  patients
with  HPS  had  a  median  survival  of  24  months  and  a  5-
year  survival  of  23%.69 Even  after  LT,  patients  with  HPS
tend  to  do  worse  than  patients  without  HPS,  even  in
those  patients  with  improved  post-transplant  arterial  oxy-
genation  (PaO2 >  50),70 with  high  postoperative  mortality,
mostly  within  the  ﬁrst  3  months  after  surgery.  In  a  large
retrospective  study,  the  1-  and  4-year  morality  was  38.5%
and  42.3%,  compared  with  patients  without  HPS,  who  had
1-  and  4-year  mortality  rates  of  0%  and  20%,  respectively.71
In  spite  of  these  ﬁndings,  LT  does  alter  the  natural  course
of  HPS,  and  thus  has  become  the  treatment  of  choice
for  HPS  in  many  centers.  Certainly,  in  selected  cases,
successful  LT  has  resulted  in  complete  resolution  of  HPS
in  the  majority  of  survivors  of  the  early  post-surgical
period.18
The  causes  of  death  associated  with  HPS  are  usually
multifactorial  and  related  to  the  complications  of  liver
disease  (e.g.  hepatic  failure,  multisystem  organ  failure
due  to  sepsis,  hepatocellular  carcinoma,  gastrointestinal
bleeding),  much  more  so  than  pulmonary  complications.
Although  oxygenation  usually  worsens  over  time  (mean
decline  of  5.2  mmHg  per  year),  it  is  not  common  for  severe
hypoxemic  respiratory  failure  to  be  the  primary  cause  of
death.18
Diagnosis
The  diagnosis  of  HPS  requires  the  presence  of  abnormal
arterial  gas  exchange  associated  with  evidence  of  IPVD,  as
described  in  the  section  on  ‘‘deﬁnition  of  HPS’’.
A  recent  prospective  study,  using  an  oxygen  saturation
(SpO2)  threshold  value  of  <95%  was  highly  sensitive  (100%)
and  speciﬁc  (88%)  to  detect  HPS  in  patients  with  PaO2
<60  mmHg  and  resulted  in  arterial  blood  testing  in  only  13%
of  the  cohort.72 SpO2 can  thus  help  as  a  screening  tool
for  HPS  and  allow  clinicians  to  select  patients  that  require
further  diagnostic  work-up  based  on  the  results  of  pulse
oximetry  on  room  air.  These  would  include  arterial  blood  gas
analysis,  echocardiography  and/or  nuclear  medicine  scan-
ning  as  described  below.
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The usual  methods  to  demonstrate  IPVD  in  the  clinic
re  contrast-enhanced  echocardiography  and  nuclear
edicine  with  radionuclide-labeled  albumin  particles.
ontrast-enhanced  echocardiography  (transthoracic  or
ransesophageal  echocardiogram,  TTE  or  TEE)  represents
he  most  sensitive  method  of  detecting  IPVD.  It  is  per-
ormed  by  IV  injection  of  contrast  material,  usually  agitated
aline  that  forms  a  stream  of  micro-bubbles  60--150  m  in
iameter,  or  indocyanine  green  dye.  Under  normal  circum-
tances  the  contrast  opaciﬁes  only  the  right  heart  chambers
ecause  the  contrast  is  ﬁltered  by  the  pulmonary  capillary
ed;  however,  the  contrast  will  opacify  the  left  heart  if  a
ight-to-left  cardiac  shunt  is  present,  generally  appearing
n  the  left  heart  within  three  heart  beats  after  injection.
hen  an  intrapulmonary  shunt  is  present,  contrast  gen-
rally  appears  in  the  left  heart  three  to  six  heart  beats
fter  its  appearance  in  the  right  heart.  In  the  context  of
atient  with  liver  disease,  detection  of  an  intrapulmonary
ight-to-left  shunt  is  considered  indicative  of  IPVDs.73 TTE
s  generally  preferred  because  it  is  less  invasive,  although
EE  detects  IPVDs  with  greater  speciﬁcity  due  to  direct
isualization  of  micro-bubbles  within  the  pulmonary  veins
s  they  enter  the  left  atrium,  and  the  result  may  be  more
ensitive  when  performed  in  the  upright  position  than  in  the
upine  position.74,75 The  detection  of  IPVDs  by  this  method
n  patients  with  liver  disease  is  insufﬁcient  to  diagnose  HPS;
mpaired  oxygenation  is  also  required.
Another  method  for  detecting  IPVD  is  radionuclide  lung
erfusion  scanning,  using  technetium-labeled  macroaggre-
ated  albumin  particles  (MAA).  This  technique  involves
ntravenously  injecting  albumin  macroaggregates  that
hould  be  trapped  in  the  pulmonary  capillary  bed,  since
he  20--50  m  diameter  of  the  macroaggregates  exceeds  the
ormal  pulmonary  capillary  diameter  of  8--15  m.  Scans  that
dentify  uptake  of  the  radionuclide  by  the  kidneys  and/or
rain  suggest  that  macroaggregates  passed  through  either
n  intrapulmonary  or  intracardiac  shunt.  The  MAA  scanning
ffers  an  advantage  over  TTE/TEE;  a  positive  scan  (shunt
raction  >6%)  is  speciﬁc  for  the  presence  of  HPS  even  in
he  context  of  intrinsic  lung  disease;  however,  technetium-
abeled  macroaggregated  albumin  scanning  has  the  inability
o  distinguish  intrapulmonary  from  intracardiac  shunts  and
as  lower  sensitivity  than  contrast-enhanced  TTE/TEE.76
n  potential  LT  candidates,  regardless  of  the  presence
r  absence  of  symptoms,  screening  for  HPS  is  important
nd  cost-effective.77 There  is  no  standard  pre-transplant
creening  for  cardiopulmonary  disease,  and  methods  and
riteria  used  vary  from  center  to  center.  Nonetheless,
etecting  all  HPS  patients  by  applying  a  diagnostic  thresh-
ld  of  a  resting  PaO2 <  70  mmHg  during  liver  transplantation
valuation  is  a  reasonable  goal  to  identify  patients  who  will
ualify  for  liver  transplant  and  for  whom  MELD  exception
riteria  may  apply.62
reatment
here  are  no  effective  medical  therapies  for  HPS,  although
any  approaches  have  been  attempted  to  improve  gas
xchange  and  decrease  hypoxemia.  LT  offers  the  most
romise  for  the  successful  treatment  of  selected  patients
ith  HPS  (see  below).
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edical  therapy
nhaled  NO,  somatostatin,  almitrine,  indomethacin,  aspirin,
 blockers,  norﬂoxacin,  and  plasma  exchange  have  all  been
ried  without  clear  beneﬁt.62 In  one  study,  pentoxifylline  was
ssociated  with  improvement  in  gas  exchange  in  patients
ith  HPS,78 but  another  study  noted  no  improvement  of
rterial  gas  exchange  and  poor  tolerability  because  of  gas-
rointestinal  toxicity.79
nvasive  therapy
lthough  improvement  of  HPS  has  been  reported  in  a  few
ases  where  TIPS  were  placed,  there  is  no  clear  beneﬁt  to
upport  the  role  of  this  strategy  in  the  routine  management
f  patients  with  HPS.  Furthermore,  the  risk  of  exacerbat-
ng  the  hyperdynamic  circulatory  state  typical  of  advanced
iver  disease,  and  thereby  enhancing  pulmonary  vasodilata-
ion  and  increasing  the  severity  of  the  HPS,  do  not  provide
upport  for  its  use  as  a  palliative  strategy  either.80
In  the  case  of  HPS  associated  with  angiographically  visible
nd  discrete  pulmonary  arteriovenous  shunts,  embolization
y  interventional  radiology  with  closure  of  such  communi-
ations  has  been  shown  to  improve  arterial  oxygenation,  at
east  temporarily  in  some  cases.81
PS  and  liver  transplantation
T  is  currently  the  only  proven  effective  therapy  for
PS  and  should  be  considered  when  severe  hypoxemia  is
resent;  it  has  been  associated  with  improvement  in  arte-
ial  gas  exchange  in  over  85%  of  patients,  with  subsequent
esolution  or  improvement  of  hypoxemia.  In  the  largest
ingle-institution  series,  patients  with  HPS  had  a  5-year  sur-
ival  of  76%  after  LT,  a  rate  not  signiﬁcantly  different  from
hat  reported  in  LT  recipients  without  HPS.69 The  sever-
ty  of  preoperative  hypoxemia,  underlying  liver  disease  and
omorbidities  appear  to  be  factors  that  increase  postopera-
ive  mortality.62
In  the  United  States,  UNOS  allows  patients  with  conﬁrmed
PS  be  listed  for  LT.  When  PaO2 <60  mmHg  on  room  air  in
he  sitting  position,  patients  can  receive  exception  MELD
cores,  starting  at  22  points  with  upgrades  of  2--3  MELD
oints  allowed  every  3  months  while  PaO2 <60  mmHg  and
ntil  LT  is  performed.  Each  upgrade  is  equivalent  to  a  10%
ortality  increase  on  the  waiting  list.82
In  patients  with  HPS  who  have  undergone  LT,  the  peri-
perative  period  may  present  particular  clinical  challenges,
orsening  hypoxemia  may  occur  in  the  early  postoperative
eriod  and  many  patients  recover  slowly  resulting  in  pro-
onged  intensive  care  unit  stay  and  unique  postoperative
omplications.  As  such,  these  patients  should  be  cared  for  in
iver  transplant  centers  with  expertise  in  the  management
f  HPS  and  its  complications.
onclusioniver  disease  and  portal  hypertension  are  associated  with
ypoxemia  through  several  mechanisms,  with  pulmonary
ascular  complications  conferring  the  greatest  impact  on
1M.  Porres-Aguilar  et  al.
rognosis  in  such  patients.  POPH  and  HPS  are  relatively  com-
on  cardiopulmonary  complications,  particularly  if  proper
nd  adequate  screening  is  made  in  LT  referral  centers,
here  the  prevalence  has  been  shown  to  be  the  highest.
OPH  and  HPS  should  be  sought  routinely  as  part  of  the
valuation  of  patients  being  considered  for  LT  as  most  cases
re  asymptomatic  or  present  with  nonspeciﬁc  symptoma-
ology.  Understanding  the  hemodynamic  diagnostic  criteria
or  POPH  is  paramount  for  adequate  therapeutic  decision-
aking  and  to  consider  withdrawing  LT  in  the  most  severe
tages  of  POPH.  In  contrast,  the  more  severe  forms  of  HPS
epresent  an  absolute  indication  for  LT,  being  the  deﬁni-
ive  invasive  therapy  for  HPS.  Novel  PAH-speciﬁc  therapies
or  POPH  represent  an  evolving  area  of  clinical  research,
xpanding  the  pool  of  potentially  transplantable  patients
fﬂicted  with  POPH,  with  the  primary  goal  of  improving
atient  survival.
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